The Data Management core activities are performed by the Data Management Center of the ECOG- ACRIN Statistics and Data Management Center. The Data Management Center is responsible for collection and processing of data on ECOG-ACRIN studies and for related information systems support. The Center has two components. SDMC-EAMRF at the ECOG-ACRCIN Medical Research Foundation has primary responsibility for therapeutic studies. The SDMC-ACR at the American College of Radiology has primary responsibility for diagnostic and imaging studies. All clinical data on studies activated since the start of the NCTN is collected and managed in Medidata Rave, the NCTN's common Clinical Data Management System. ECOG-ACRIN has been a leader in developing configuration standards and operational procedures for using Rave in the NCTN. Data review procedures are well developed and include clinical review, which is usually performed by study chairs. The Data Management core has established extensive education and training programs for site personnel and investigators. These training programs are an important part of ensuring timely and accurate data submission and review. The data management core has also developed reports for monitoring site performance regarding timeliness and accuracy of data submission, and works with the ECOG-ACRIN Operations on the annual institution evaluation. The Statistics and Data Management Center also fully utilizes standard NCTN tools, such as the Oncology Patient Enrollment Network (the web interface for patient enrollment on NCTN studies), the Cancer Data Standards Repository library of standardized data elements, the common toxicity criteria for adverse events, the CTEP-AERS system for adverse event reporting, which is being integrated into Rave), and the Clinical Data Update System for reporting selected trial and patient data to NCI. The Information Systems group maintains multiple databases, develops and maintains tools for monitoring, reporting, and communication, and has developed infrastructure to support complex trials such as NCI- MATCH.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180794-06
Application #
9627515
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-04-04
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Ratai, Eva-Maria; Zhang, Zheng; Fink, James et al. (2018) ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. PLoS One 13:e0198548
King, Rebecca L; Nowakowski, Grzegorz S; Witzig, Thomas E et al. (2018) Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J 8:27
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Marcelletti, John F; Sikic, Branimir I; Cripe, Larry D et al. (2018) Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry B Clin Cytom :
Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087

Showing the most recent 10 out of 187 publications